Colorectal cancer (CRC) remains the second leading cause of cancer death in the United States, yet it is one of the most preventable and curable cancers when detected early. The 2023 USPSTF guidelines recommend beginning screening at age 45 (lowered from 50 in 2021) for average-risk adults through age 75, and shared decision-making for ages 76–85. The pivotal challenge for clinicians and patients: which screening modality to choose from a menu that has expanded significantly with molecular stool testing options.
Colonoscopy: Gold Standard With Important Caveats
Colonoscopy allows detection AND polypectomy in a single procedure, enabling both diagnosis and prevention. Detection rates: 95% for cancers, 85–90% for large adenomas (≥10mm). The NordICC trial (2022, New England Journal of Medicine, n=84,585) — the first RCT of colonoscopy screening — delivered a sobering finding: intention-to-screen analysis showed only 18% reduction in CRC risk (not the 50–70% reduction seen in observational studies). Per-protocol analysis (those who actually underwent colonoscopy) showed 31% reduction. The gap reflects low adherence in the colonoscopy-invited group. Right-sided colon cancers are more frequently missed due to serrated polyp morphology and difficult visualization around haustral folds — flat serrated adenomas account for 20–30% of colonoscopy-interval cancers.
Cologuard and FIT: Noninvasive Options
FIT (fecal immunochemical test): annual testing, 79% sensitivity and 94% specificity for CRC; good evidence from case-control studies showing 67–79% CRC mortality reduction with consistent annual testing. Cost-effective, no bowel prep, no sedation — but requires annual repetition (adherence challenge) and every positive requires colonoscopy. Cologuard (mt-sDNA, Exact Sciences): combines FIT with methylated DNA markers (NDRG4, BMP3) and mutation testing (KRAS). Sensitivity 92% for CRC, 66% for advanced adenomas versus FIT's 79% and 24% — significantly more sensitive but with higher false-positive rate (13% vs 5% for FIT), leading to more colonoscopies in healthy individuals. Every 1–3 years per FDA labeling. The BLUE-C trial comparing next-generation Cologuard to colonoscopy is underway. For clinical facilities managing CRC screening programs, our laboratory supplies section includes specimen collection kits, and our diagnostic equipment section supports clinical screening workflows.
